scholarly journals Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis

2018 ◽  
Vol 9 (1) ◽  
pp. 243-247 ◽  
Author(s):  
Daisuke Sora ◽  
Kei Takayama ◽  
Manzo Taguchi ◽  
Tomohito Sato ◽  
Yutaka Sakurai ◽  
...  
Keyword(s):  
Topical Corticosteroid ◽  
Anterior Uveitis ◽  
Inflammatory Cells ◽  
Corticosteroid Treatment ◽  
Neovascular Glaucoma ◽  
Blurred Vision ◽  
Rubeosis Iridis ◽  
Granulomatous Uveitis ◽  
First Choice ◽  
Polymerase Chain

Purpose: We report a case of topical corticosteroid treatment-resolved rubeosis iridis with neovascular glaucoma (NVG) caused by noninfectious granulomatous uveitis. Case Report: A 61-year-old woman with left ocular pain and blurred vision was referred to our department. Visual acuity and intraocular pressure (IOP) were 20/60 and 37 mm Hg in the left eye, respectively. Inflammatory cells, hyphema, and rubeosis iridis were observed. All laboratory tests, including multiplex polymerase chain reaction for infection using aqueous humor, were negative, and there was neither retinal occlusive vasculitis nor retinal ischemia in the fundus. Our diagnosis was noninfectious granulomatous anterior uveitis-associated NVG. Topical corticosteroid treatment and anti-glaucoma agents resolved inflammation, rubeosis iridis, and NVG. IOP had decreased to 13 mm Hg by 1 month of treatment, and no recurrence was observed. Conclusion: Topical corticosteroid could resolve rubeosis iridis and NVG in an eye with noninfectious anterior uveitis. The pathogenesis of NVG in eyes with uveitis is still unknown, but inflammation might have a part in angiogenesis. Anti-inflammatory treatment can be selected as the first choice for anterior uveitis-associated NVG.

Juvenile Idiopathic Arthritis associated Uveitis: Diagnosis, Clinic, and Treatment

2020 ◽  
pp. 260-262
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Surgical Treatment ◽  
Topical Corticosteroid ◽  
Immunosuppressive Therapy ◽  
Corticosteroid Therapy ◽  
Anterior Uveitis ◽  
Biological Agents ◽  
Second Step ◽  
Insidious Onset ◽  
First Choice

Uveitis is the most common extraarticular finding in juvenile idiopathic arthritis (JIA). Non-granulomatous, chronic, insidious onset of anterior uveitis does not show any symptoms, so complications are often seen at the time of diagnosis. Therefore, periodic screening is necessary in JIA cases. Topical corticosteroid therapy is the first approach when diagnosed early and immunosuppressive therapy is necessary if remission cannot be achieved or if there is an initial complication. For this purpose, the first choice is methotrexate and the second step is biological agents such as adalimumab or infliximab. Surgical treatment is required for complications such as cataract and glaucoma.

scholarly journals Cyclo-oxygenase 2, a putative mediator of vessel remodeling, is expressed in the brain AVM vessels and associates with inflammation

2021 ◽  
Author(s):  
Sara Keränen ◽  
Santeri Suutarinen ◽  
Rahul Mallick ◽  
Johanna P. Laakkonen ◽  
Diana Guo ◽  
...  
Keyword(s):  
Quantitative Polymerase Chain Reaction ◽  
Rank Correlation ◽  
Inflammatory Cells ◽  
Vessel Remodeling ◽  
Brain Avm ◽  
Inflammatory Drugs ◽  
Polymerase Chain ◽  
The Brain ◽  
Cox2 Expression

Abstract Background Brain arteriovenous malformations (bAVM) may rupture causing disability or death. BAVM vessels are characterized by abnormally high flow that in general triggers expansive vessel remodeling mediated by cyclo-oxygenase-2 (COX2), the target of non-steroidal anti-inflammatory drugs. We investigated whether COX2 is expressed in bAVMs and whether it associates with inflammation and haemorrhage in these lesions. Methods Tissue was obtained from surgery of 139 bAVMs and 21 normal Circle of Willis samples. The samples were studied with immunohistochemistry and real-time quantitative polymerase chain reaction (RT-PCR). Clinical data was collected from patient records. Results COX2 expression was found in 78% (109/139) of the bAVMs and localized to the vessels’ lumen or medial layer in 70% (95/135) of the bAVMs. Receptors for prostaglandin E2, a COX2-derived mediator of vascular remodeling, were found in the endothelial and smooth muscle cells and perivascular inflammatory cells of bAVMs. COX2 was expressed by infiltrating inflammatory cells and correlated with the extent of inflammation (r = .231, p = .007, Spearman rank correlation). COX2 expression did not associate with haemorrhage. Conclusion COX2 is induced in bAVMs, and possibly participates in the regulation of vessel wall remodelling and ongoing inflammation. Role of COX2 signalling in the pathobiology and clinical course of bAVMs merits further studies.

Rubeosis iridis and macular hemorrhages from multiple Corkscrew retinal vessels in a patient with NF1

2021 ◽  
pp. 112067212199663
Author(s):  
Marilyn A Márquez ◽  
Claudio P Juárez ◽  
Maria C Sánchez ◽  
Jose D Luna
Keyword(s):  
Intravitreal Bevacizumab ◽  
Visual Outcome ◽  
Neovascular Glaucoma ◽  
Retinal Vessels ◽  
Retinal Hemorrhages ◽  
Fluorescein Angiogram ◽  
Rubeosis Iridis ◽  
Good Visual Outcome ◽  
Av Malformation ◽  
Sudden Decrease

Purpose: To report a case of a patient with NF1 presenting with ocular findings of AV malformation, multiple retinal hemorrhages, and neovascular glaucoma in the absence of retinal ischemia. Methods: Review of the medical record was conducted in accordance with the local IRBt. Results: A 60-year-old female patient with diagnosis of Neurofibromatosis type1 (NF1) and sudden decrease of vision in her left eye was found to have rubeosis iridis and high intraocular pressure (IOP). On fundus exam multiple corkscrew retinal vessels and retinal hemorrhages were present in her left eye. On Optical Coherence Tomography (OCT) the foveal hemorrhages appeared as outer layer hyperreflective retinal infiltrates whereas in the parafoveal area the hyperreflectivity was present between the RPE and neurosensory retina. Fluorescein Angiogram (FA) showed normal perfusion and no areas of leakage or ischemia. Treatment with anti-angiogenics in a timely manner correlated with a good visual outcome. Conclusions: We present a unique patient with NF1, rubeosis iridis, high IOP, and macular hemorrhages from multiple corkscrew retinal vessels in a well perfused retina, who underwent treatment with a single dose of intravitreal Bevacizumab and had an excellent response

Familial high serum PICP: high even in skin interstitial fluid, suppressible by topical corticosteroid treatment

2001 ◽  
Vol 314 (1-2) ◽  
pp. 153-157 ◽  
Author(s):  
Antti Sorva ◽  
Ritva Sorva ◽  
Juha Risteli ◽  
Leila Risteli ◽  
Pekka Autio
Keyword(s):  
Topical Corticosteroid ◽  
Interstitial Fluid ◽  
Corticosteroid Treatment ◽  
High Serum

The Efficacy of Subconjunctival Bevacizumab in the Management of Rubeosis Iridis and Neovascular Glaucoma

2019 ◽  
Vol 26 (1) ◽  
pp. 18-24
Author(s):  
Khatatbeh , Ahmed E. ◽  
Otoum , Marwan ◽  
Al Zweimel , Fawaz ◽  
Haddad , Hala ◽  
Rwashdeh , Hesham
Keyword(s):  
Neovascular Glaucoma ◽  
Rubeosis Iridis

Lens and Anterior Uvea

2022 ◽  
pp. 359-392
Keyword(s):  
Macular Edema ◽  
Anterior Uveitis ◽  
Clinical Signs ◽  
Inflammatory Cells ◽  
Clinical Findings ◽  
Eye Drops ◽  
Systemic Diseases ◽  
Intravitreal Triamcinolone ◽  
Keratic Precipitates ◽  
Intravitreal Triamcinolone Injection

This chapter illustrates photos of clinical signs seen in uveitis and interesting cases of lens pathologies. Anterior uveitis is the inflammation of the iris and the ciliary body. Anterior uveitis can be idiopathic, isolated, or associated with systemic diseases. The clinical findings observed in anterior uveitis include keratic precipitates, inflammatory cells and flare in anterior chamber, hypopyon, rarely hyphema, miosis, iris nodules and atrophy, synechiae, and band keratopathy in chronic cases (shown in corneal degenerations chapter). The inflammation in anterior uveitis is almost always immune. Treatment includes steroid eye drops, cycloplegic drops, sub-Tenon steroid injections when cystoid macular edema is present. Chronic macular edema can be treated with intravitreal Triamcinolone injection and Dexamethasone implants. In cases of refractory anterior uveitis or associated immune systemic diseases, immunomodulatory treatment or biologic agents are prescribed.

290 COMPARATIVE EFFICACY OF CORTICOSTEROIDS FORMULATIONS FOR THE MANAGEMENT OF EOSINOPHILIC OESOPHAGITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.

2020 ◽  
Vol 33 (Supplement_1) ◽  
Author(s):  
C Ma ◽  
B Feagan ◽  
D Claveau ◽  
L Landry ◽  
V Baribeau ◽  
...  
Keyword(s):  
Topical Corticosteroid ◽  
Controlled Trial ◽  
Meta Analysis ◽  
Adult Patients ◽  
Eosinophilic Oesophagitis ◽  
High Power Field ◽  
Topical Corticosteroids ◽  
Randomized Controlled ◽  
First Choice ◽  
Histological Remission

Abstract   Topical corticosteroids are the foundation of pharmacologic treatment for eosinophilic oesophagitis (EoE) and administered mainly as nebulized swallowed fluticasone or budesonide viscous solution (BVS). Recently, a budesonide orodispersible tablet (BOT) has been approved for the treatment of EoE. The ideal formulation of topical corticosteroid delivery is unclear. Therefore, we aimed to compare the efficacy of BOT with other topical corticosteroid formulations for achieving histological remission in adult patients with EoE in a network meta-analysis (NMA). Methods A systematic literature review was performed using Medline and EMBASE from 1990 to July 2019. Eligible studies evaluated adult patients with a diagnosis of EoE treated with a topical corticosteroid in a randomized controlled trial. The outcome of interest was the proportion of patients achieving induction of histological remission (peak esophageal eosinophil count <5 eosinophils/high-power field). Direct comparisons were performed using the Mantel–Haenszel method and an NMA was performed using a fixed effect Bayesian framework with Markov Chain Monte Carlo simulations. Heterogeneity between studies was analyzed using the Cochrane Q test and consistency was verified. Results The search yielded 321 references and 6 (447 patients) were included in the quantitative summary. In the NMA, all formulations of topical corticosteroids were associated with greater histological remission rates than placebo. BOT was associated with a significantly higher rate of histological remission compared to BVS (odds ratio [OR] = 4.9; 95% credible interval [CrI] = 1.4,19.1), fluticasone (OR = 7.4; 95%CrI = 1.7,34.5), nebulized swallowed budesonide (NSB) (OR = 25.0; 95%CrI = 2.9,247.2) and placebo (OR = 387.6; 95%CrI = 97.5,2275.6). Similar trends were shown in direct comparisons. Analysis of the ranking of treatment options based on probability of effectiveness found BOT to be most probable followed by BVS, fluticasone, NSB, and placebo, consecutively. Conclusion This NMA of randomized controlled trials suggests that BOT is significantly more likely to achieve histological remission in adult patients with EoE compared to BVS, fluticasone, and NSB. We hypothesize that the superiority of BOT is related to increased contact time and targeting all inflammatory sites in the oesophagus, in contrast to other formulations. This NMA suggest that BOT is the first choice therapy amongst topical corticosteroids for the management of EoE.

Antimicrobial Silk Clothing in the Treatment of Atopic Dermatitis Proves Comparable to Topical Corticosteroid Treatment

Dermatology ◽  
2006 ◽  
Vol 213 (3) ◽  
pp. 228-233 ◽  
Author(s):  
G. Senti ◽  
L.S. Steinmann ◽  
B. Fischer ◽  
R. Kurmann ◽  
T. Storni ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Topical Corticosteroid ◽  
Corticosteroid Treatment
Sign in / Sign up

Export Citation Format

Share Document